Infectious Disease Archives

Publication

Population Pharmacokinetics of Ceftolozane/Tazobactam in Healthy Volunteers, Subjects with Varying Degrees of Renal Function and Patients with Bacterial Infections

Ceftolozane/tazobactam is a novel antipseudomonal cephalosporin and a β-lactamase inhibitor in clinical development for treatment…

CertaraFebruary 1, 2015

Publication

Pharmacokinetics of Injectable, Long-acting Nevirapine for HIV Prophylaxis in Breastfeeding Infants

Mother-to-child transmission (MTCT) of HIV-1 remains a global health problem. The World Health Organization (WHO…

CertaraJanuary 1, 2015

Publication

Pharmacokinetics of Vancomycin in Critically Ill Patients in Thailand

The pharmacokinetics and pharmacodynamics of drugs in critically ill patients are difficult to predict due…

CertaraDecember 1, 2014

Publication

Characterization of the Transmembrane Transport and Absolute Bioavailability of the HCV Protease Inhibitor Danoprevir

CertaraDecember 1, 2014

Publication

Pharmacokinetics and Pharmacodynamics of Setrobuvir, an Orally Administered Hepatitis C Virus Non-nucleoside Analog Inhibitor

CertaraDecember 1, 2014

Publication

Meropenem in Children Receiving Continuous Renal Replacement Therapy: Clinical Trial Simulations Using Realistic Covariates

Meropenem is frequently prescribed in children receiving continuous renal replacement therapy (CRRT). Fluid overload is…

CertaraDecember 1, 2014

Publication

A Pharmacokinetic/Viral Kinetic Model to Evaluate the Treatment Effectiveness of Danoprevir Against Chronic HCV

CertaraOctober 16, 2014

Publication

Understanding the Effect of the HCV Polymerase Inhibitor Mericitabine on Early Viral Kinetics in the Phase 2 JUMP-C and PROPEL Studies

CertaraAugust 21, 2014

Publication

Comparative Benefit of Malaria Chemoprophylaxis Modeled in United Kingdom Travelers

CertaraAugust 5, 2014

Publication

Activities of Ceftazidime and Avibactam Against β-lactamase-producing Enterobacteriaceae in a Hollow-fiber Pharmacodynamic Model

Avibactam is a novel non-β-lactam β-lactamase inhibitor that is currently undergoing phase 3 clinical trials…

CertaraJune 1, 2014

Infectious Disease

Population Pharmacokinetics of Ceftolozane/Tazobactam in Healthy Volunteers, Subjects with Varying Degrees of Renal Function and Patients with Bacterial Infections

Pharmacokinetics of Injectable, Long-acting Nevirapine for HIV Prophylaxis in Breastfeeding Infants

Pharmacokinetics of Vancomycin in Critically Ill Patients in Thailand

Characterization of the Transmembrane Transport and Absolute Bioavailability of the HCV Protease Inhibitor Danoprevir

Pharmacokinetics and Pharmacodynamics of Setrobuvir, an Orally Administered Hepatitis C Virus Non-nucleoside Analog Inhibitor

Meropenem in Children Receiving Continuous Renal Replacement Therapy: Clinical Trial Simulations Using Realistic Covariates

A Pharmacokinetic/Viral Kinetic Model to Evaluate the Treatment Effectiveness of Danoprevir Against Chronic HCV

Understanding the Effect of the HCV Polymerase Inhibitor Mericitabine on Early Viral Kinetics in the Phase 2 JUMP-C and PROPEL Studies

Comparative Benefit of Malaria Chemoprophylaxis Modeled in United Kingdom Travelers

Activities of Ceftazidime and Avibactam Against β-lactamase-producing Enterobacteriaceae in a Hollow-fiber Pharmacodynamic Model

Newsletter sign up

Quick links

Solutions

Contact